BetaGlue Therapeutics develops YntraDose, a targeted nuclear radiotherapy platform that injects Yttrium‑90 microspheres embedded in a biocompatible glue directly into solid tumours. The system enables minimally invasive, imaging‑guided delivery of high‑dose beta radiation within the tumor, sparing surrounding tissue and offering a single‑session treatment option for hard‑to‑treat cancers such as pancreatic, liver and breast tumours.
Funding
Funding not disclosed
Founders
Product
Problem
Current external radiotherapy methods such as SBRT and proton therapy deliver radiation through beams that must traverse healthy tissue, limiting dose intensity for abdominal tumors and requiring costly infrastructure. Many solid‑tumor patients, especially those with pancreatic, liver or breast lesions, lack safe, localized treatment options that can be administered minimally invasively.
Solution
BetaGlue Therapeutics has created YntraDose, a targeted nuclear radiotherapy platform that injects Yttrium‑90 microspheres embedded in a biocompatible glue directly into the tumor mass. The microspheres emit beta radiation locally, providing a high therapeutic index while sparing surrounding organs. The system is designed for percutaneous or intra‑operative delivery by interventional radiologists under imaging guidance, enabling a single‑day, minimally invasive procedure. By combining radiochemistry, a polymerizing matrix, and a dedicated delivery device, YntraDose delivers a personalized radiation dose that can be tailored to each lesion. Early clinical studies in pancreatic cancer, hepatocellular carcinoma, and ductal carcinoma in situ have shown favorable safety and preliminary efficacy, supporting its potential as a new standard of care for hard‑to‑treat solid tumors.
Target Audience
Primary customers are interventional radiologists and nuclear medicine physicians treating patients with locally advanced or unresectable solid tumors, particularly in pancreatic, hepatic and early‑stage breast cancer settings.
Features
- Sterile vial of Yttrium‑90 microspheres providing a fixed radioactive dose
- Biocompatible bioglue that polymerizes in situ to retain microspheres at the injection site
- Double‑barrel mixing syringe (YntraDose‑Glue) that combines microspheres and glue immediately before administration
- Dedicated delivery tip (YntraDose‑Deliver) compatible with standard interventional needles for precise percutaneous or intra‑operative injection
- Imaging‑guided workflow (localize, prepare, treat, assess) that integrates with existing radiology suites
- Single‑session treatment delivering high‑dose radiation directly within the tumor, eliminating off‑target exposure
- Applicable across multiple solid‑tumor anatomies (pancreas, liver, breast) and adaptable to future indications